Skip to main content
. 2008 Mar 19;15(5):773–782. doi: 10.1128/CVI.00020-08

FIG. 1.

FIG. 1.

CD8 cells in PBMC reactive in IFN-γ ELISPOT with peptide gB2 442-451 prior to and 24 weeks after vaccination with AG-702 or control peptide. Each panel represents one dose level and subject group as indicated. Individual subjects each have a colored line. Data are mean peptide-specific sfu per 106 CD8 PBMC. Note the association of the y-axis scale with subjects’ HSV serostatus.